Evidence map›Paper›PMID 29430530›Full record

ArticleeNeurologicalSci2016

Does the survival motor neuron copy number variation play a role in the onset and severity of sporadic amyotrophic lateral sclerosis in Malians?

Modibo Sangare, Ilo Dicko, Cheick Oumar Guinto, Adama Sissoko, Kekouta Dembele, Youlouza Coulibaly, Siaka Y Coulibaly, Guida Landoure, Abdallah Diallo, Mamadou Dolo and 23 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eNeurologicalSci, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 5 institutions in 2 countries.

Modibo SangareFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Ilo DickoFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Cheick Oumar GuintoNeurology department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Adama SissokoNeurology department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Kekouta DembeleNeurology department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Youlouza CoulibalyFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Siaka Y CoulibalyFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Guida LandoureNeurology department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Abdallah DialloFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Mamadou DoloFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Housseini DoloFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Boubacar MaigaNeurology department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Moussa TraoreNeurology department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Mamadou KarembeNeurology department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Kadiatou TraorePsychiatry department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Amadou TourePediatry department, Teaching hospital Gabriel Touré, Bamako, Mali.
Mariam SyllaPediatry department, Teaching hospital Gabriel Touré, Bamako, Mali.
Arouna TogoraPsychiatry department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Souleymane CoulibalyPsychiatry department, Teaching hospital of Point G, Village Point G, Bamako, Mali.
Sékou Fantamady TraoreMalaria Research and Training Center, Faculty of Medicine, USTTB, Bamako, Mali.
Brant HendricksonLabCorp, Boston, MA, United States.
Katherine BriccenoNeurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, United States.
Alice B SchindlerNeurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, United States.
Angela KokkinisNeurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, United States.
Katherine G MeilleurNeurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, United States.
Hammadoun Ali SanghoDepartment of Education and Research in Public Health, Faculty of Medicine, USTTB, Bamako, Mali.
Brehima DiakiteFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Yaya KassogueFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Yaya Ibrahim CoulibalyFaculty of Medicine, University of Sciences Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Barrington BurnettNeurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, United States.
Youssoufa MaigaNeurology department, Teaching hospital Gabriel Touré, Bamako, Mali.
Seydou DoumbiaDepartment of Education and Research in Public Health, Faculty of Medicine, USTTB, Bamako, Mali.
Kenneth H FischbeckNeurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, United States.
Université des Sciences, des Techniques et des Technologies de Bamako · MLNational Institute of Neurological Disorders and Stroke · USLabCorp (United States) · USMali-Folkecenter · MLUniversity of Bamako · ML

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSpinal muscular atrophy (SMA) and sporadic amyotrophic lateral sclerosis (SALS) are both motor neuron disorders. SMA results from the deletion of the survival motor neuron (

objectiveTo investigate the role of MATERIAL AND

methodsWe determined the

resultsWe found that 131 of 391 (33.5%) had an estimated SMN protein expression of ≤ 2.2; 60 out of 391 (15.3%) had an estimated SMN protein expression < 2 and would be at risk of ALS and the disease onset was as early as 16 years old. All 15 patients were male and some were physically handicapped within 1-2 years in the disease course.

conclusionBecause of the short survival time of our patients, family histories and sample DNA for testing were not done. However, our results show that sporadic ALS is of earlier onset and shorter survival time as compared to patients elsewhere. We plan to establish a network of neurologists and researchers for early screening of ALS.

Indexed as

SALSSMASMN1SMN2Veldink formula

Identifiers

PMID29430530
PMCPMC5803066
OpenAlexW2260504733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.